Stockreport

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

EyePoint Pharmaceuticals, Inc.  (EYPT) 
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF – Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiati [Read more]